This document provides an overview and discussion of refractory status epilepticus (RSE) and non-convulsive status epilepticus (NCSE). It defines these conditions and reviews their clinical characteristics, pathophysiology, treatment options including antiepileptic drugs, anesthesia, surgery, hypothermia and immunotherapy. It examines factors that influence prognosis and outcomes such as etiology, age, seizure duration and EEG findings. It suggests RSE treatment should be guided by etiology, duration of seizures and EEG characteristics as these most influence patient prognosis and recovery.
Brief Report: OSA Evaluations for the Anaesthesiologist, Surgeon, Surgery Centresemualkaira
This short report presents a scope of the medical condition of Obstructive Sleep Apnea (OSA). Current methods for assessment and
diagnosis of OSA are presented. Complications and potential death
from untreated OSA places the anesthesiologist, surgeon and surgical center in a risk situation. Factors related to the risk factors
and points toward resolution are presented.
A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...Dr. Rafael Higashi
Aula apresentada por Dr. Rafael Higashi, médico neurologista sobre quando retirar droga antiepilética. A guideline for discontinuing antiepileptic drugs in seizure-free patients – Summary Statement
Parkinson's disease is a brain disorder that progressively affects a person’s ability to control body movements, caused by a disorder of certain nerve cells in a part of the brain that produces dopamine, a chemical messenger the brain uses to help direct and control body movement.
Early diagnosis of Parkinson's disease gives you the best chance of a longer, healthier life. This presentation covers the information about biomarkers for Parkinson Diseases which include biological, physiological and imagine candidate / novel biomarkers.
Brief Report: OSA Evaluations for the Anaesthesiologist, Surgeon, Surgery Centresemualkaira
This short report presents a scope of the medical condition of Obstructive Sleep Apnea (OSA). Current methods for assessment and
diagnosis of OSA are presented. Complications and potential death
from untreated OSA places the anesthesiologist, surgeon and surgical center in a risk situation. Factors related to the risk factors
and points toward resolution are presented.
A guideline for discontinuing antiepileptic drugs in seizure-free patients – ...Dr. Rafael Higashi
Aula apresentada por Dr. Rafael Higashi, médico neurologista sobre quando retirar droga antiepilética. A guideline for discontinuing antiepileptic drugs in seizure-free patients – Summary Statement
Parkinson's disease is a brain disorder that progressively affects a person’s ability to control body movements, caused by a disorder of certain nerve cells in a part of the brain that produces dopamine, a chemical messenger the brain uses to help direct and control body movement.
Early diagnosis of Parkinson's disease gives you the best chance of a longer, healthier life. This presentation covers the information about biomarkers for Parkinson Diseases which include biological, physiological and imagine candidate / novel biomarkers.
A review of epilepsy in the elderly, the etiopathogenesis, clinical challenges, diagnosis, use of antiseizure drugs and outcomes. Also the various special considerations in managing elderly patients with epilepsy.
REVIEWpublished 24 June 2015doi 10.3389fnhum.2015.003.docxmalbert5
REVIEW
published: 24 June 2015
doi: 10.3389/fnhum.2015.00359
Pathophysiology of ADHD and
associated problems—starting points
for NF interventions?
Björn Albrecht*, Henrik Uebel-von Sandersleben, Holger Gevensleben and
Aribert Rothenberger
Department of Child and Adolescent Psychiatry, University Medical Center Göttingen, Göttingen, Germany
Edited by:
Martijn Arns,
Research Institute Brainclinics,
Netherlands
Reviewed by:
Roumen Kirov,
Institute of Neurobiology, Bulgarian
Academy of Sciences, Bulgaria
Leon Kenemans,
Utrecht University, Netherlands
*Correspondence:
Björn Albrecht,
Department of Child and Adolescent
Psychiatry, University Medical Center
Göttingen, von Siebold Straße 5,
37075 Göttingen, Germany
[email protected]
Received: 06 October 2014
Accepted: 02 June 2015
Published: 24 June 2015
Citation:
Albrecht B, Uebel-von Sandersleben
H, Gevensleben H and Rothenberger
A (2015) Pathophysiology of ADHD
and associated problems—starting
points for NF interventions?
Front. Hum. Neurosci. 9:359.
doi: 10.3389/fnhum.2015.00359
Attention deficit hyperactivity disorder (ADHD) is characterized by severe and
age-inappropriate levels of hyperactivity, impulsivity and inattention. ADHD is a
heterogeneous disorder, and the majority of patients show comorbid or associated
problems from other psychiatric disorders. Also, ADHD is associated with cognitive and
motivational problems as well as resting-state abnormalities, associated with impaired
brain activity in distinct neuronal networks. This needs to be considered in a multimodal
treatment, of which neurofeedback (NF) may be a promising component. During NF,
specific brain activity is fed-back using visual or auditory signals, allowing the participants
to gain control over these otherwise unaware neuronal processes. NF may be used
to directly improve underlying neuronal deficits, and/or to establish more general self-
regulatory skills that may be used to compensate behavioral difficulties. The current
manuscript describes pathophysiological characteristics of ADHD, heterogeneity of
ADHD subtypes and gender differences, as well as frequently associated behavioral
problems such as oppositional defiant/conduct or tic disorder. It is discussed how NF
may be helpful as a treatment approach within these contexts.
Keywords: Neurofeedback (NF), ADHD, ODD/CD, tic disorder, comorbidity, children, neurobiology
Introduction
Difficulties with Inattention or Hyperactivity and Impulsivity as the core symptoms of Attention
deficit Hyperactivity disorder (ADHD) are a frequent psychosocial burden. With an early onset
during childhood, ADHD is often persisting throughout life. It is a heterogeneous disorder, and a
challenge to treat. In light of this heterogeneity, the most promising treatment approach should
be multimodal in nature (Taylor et al., 2004; Swanson et al., 2008). Pharmacological interventions
particularly with stimulants such as methylphenidate and amphetamine sulfate, as well as non-
s.
Epilepsy is a chronic neurological disorder which is caused by various factors which may vary according to the age of patients which results in asynchronization of neurons. Cognitive functional impairment is mostly seen in epileptic patients compared to the general population, and the degree of its impairment varies from one another according to the epilepsy syndrome. Behavioral changes are more seen in epileptic people and people with drug-resistant epilepsy, frequent seizures, and associated neurological or mental abnormalities. In children and adults, many data suggest a correlation between behavior/cognition and some other specific epilepsy syndromes. The major predictors of such behavioral changes in children with epilepsy are epilepsy itself, treatment, the underlying structural lesion, and epilepsy treatment.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
A review of epilepsy in the elderly, the etiopathogenesis, clinical challenges, diagnosis, use of antiseizure drugs and outcomes. Also the various special considerations in managing elderly patients with epilepsy.
REVIEWpublished 24 June 2015doi 10.3389fnhum.2015.003.docxmalbert5
REVIEW
published: 24 June 2015
doi: 10.3389/fnhum.2015.00359
Pathophysiology of ADHD and
associated problems—starting points
for NF interventions?
Björn Albrecht*, Henrik Uebel-von Sandersleben, Holger Gevensleben and
Aribert Rothenberger
Department of Child and Adolescent Psychiatry, University Medical Center Göttingen, Göttingen, Germany
Edited by:
Martijn Arns,
Research Institute Brainclinics,
Netherlands
Reviewed by:
Roumen Kirov,
Institute of Neurobiology, Bulgarian
Academy of Sciences, Bulgaria
Leon Kenemans,
Utrecht University, Netherlands
*Correspondence:
Björn Albrecht,
Department of Child and Adolescent
Psychiatry, University Medical Center
Göttingen, von Siebold Straße 5,
37075 Göttingen, Germany
[email protected]
Received: 06 October 2014
Accepted: 02 June 2015
Published: 24 June 2015
Citation:
Albrecht B, Uebel-von Sandersleben
H, Gevensleben H and Rothenberger
A (2015) Pathophysiology of ADHD
and associated problems—starting
points for NF interventions?
Front. Hum. Neurosci. 9:359.
doi: 10.3389/fnhum.2015.00359
Attention deficit hyperactivity disorder (ADHD) is characterized by severe and
age-inappropriate levels of hyperactivity, impulsivity and inattention. ADHD is a
heterogeneous disorder, and the majority of patients show comorbid or associated
problems from other psychiatric disorders. Also, ADHD is associated with cognitive and
motivational problems as well as resting-state abnormalities, associated with impaired
brain activity in distinct neuronal networks. This needs to be considered in a multimodal
treatment, of which neurofeedback (NF) may be a promising component. During NF,
specific brain activity is fed-back using visual or auditory signals, allowing the participants
to gain control over these otherwise unaware neuronal processes. NF may be used
to directly improve underlying neuronal deficits, and/or to establish more general self-
regulatory skills that may be used to compensate behavioral difficulties. The current
manuscript describes pathophysiological characteristics of ADHD, heterogeneity of
ADHD subtypes and gender differences, as well as frequently associated behavioral
problems such as oppositional defiant/conduct or tic disorder. It is discussed how NF
may be helpful as a treatment approach within these contexts.
Keywords: Neurofeedback (NF), ADHD, ODD/CD, tic disorder, comorbidity, children, neurobiology
Introduction
Difficulties with Inattention or Hyperactivity and Impulsivity as the core symptoms of Attention
deficit Hyperactivity disorder (ADHD) are a frequent psychosocial burden. With an early onset
during childhood, ADHD is often persisting throughout life. It is a heterogeneous disorder, and a
challenge to treat. In light of this heterogeneity, the most promising treatment approach should
be multimodal in nature (Taylor et al., 2004; Swanson et al., 2008). Pharmacological interventions
particularly with stimulants such as methylphenidate and amphetamine sulfate, as well as non-
s.
Epilepsy is a chronic neurological disorder which is caused by various factors which may vary according to the age of patients which results in asynchronization of neurons. Cognitive functional impairment is mostly seen in epileptic patients compared to the general population, and the degree of its impairment varies from one another according to the epilepsy syndrome. Behavioral changes are more seen in epileptic people and people with drug-resistant epilepsy, frequent seizures, and associated neurological or mental abnormalities. In children and adults, many data suggest a correlation between behavior/cognition and some other specific epilepsy syndromes. The major predictors of such behavioral changes in children with epilepsy are epilepsy itself, treatment, the underlying structural lesion, and epilepsy treatment.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
5. Non-convulsive status epilepticus (NCSE)
Change in behavior and/or
mental processes from
baseline associated with
epileptiform EEG
20-25% of SE overall
8% -20% of comatose
patients
14% of GCSE patients after
controlling motor
movements
18% mortality and 39%
morbidity
Meierkord H and Holtkamp M. Lancet Neurol 2007
Schneker BF and Fountain NB. Neurology 2003
6. NCSE – When to consider
Remote risk factors for epilepsy
Intracranial tumor
Meningitis/encephalitis
MRI evidence of encephalomalacia
Previous stroke
Previous neurosurgery
History of epilepsy
Physical exam
Abnormal ocular movements
Subtle mouth movements
Severely impaired mental status
Laccheo I, et al. Neurocrit Care 2014
Husain AM, et al. JNNP 2003
Gilmore EJ, et al. Intensive Care Med 2015
8. How long should the EEG be?
Claassen J, et al. Neurology 2003
Shafi MM, et al. Neurology 2012
9. What do the EEG findings mean?
Claassen J, et al. Neurology 2003
10. Does continuous EEG result in changed
management?
One study from MGH
Changed management in 52% of cases
Started AEDs in 14%
Altered AED regimin in 33%
Stopped AEDs in 5%
One study from CHOP
Initiate or escalate AEDs in 43%
Demonstrate non-ictal behavior in 21%
Obtain urgent neuro-imaging in 3%
Kilbride RD, et al. Arch Neurol 2009
Abend NS, et al. Neurocrit Care 2011
14. RSE basic info
RSE mortality rate: 16-48%
29-33% return to baseline
SRSE has “high morbidity”, but there are “case
reports with favorable outcome”
Risk factors for developing RSE
New onset or “incident” SE
Focal motor seizures (epilepsia partialis continua)
Acute CNS disorders
Claassen J, et al. Epilepsia 2002
Hocker S, et al. Archives of Neurology 2013
Shorvon S and Ferlisi M. Brain 2011
16. RSE basic info
Etiology broadly
assigned to one of five
groups
1. Drug/toxins
Shorvon S and Ferlisi M. Brain 2011
Betjemann JP and Lowenstein DH. Lancet Neurol 2015
Turnbull D and Singatullina N. Minerva Anestesiol 2013
17. RSE basic info
Etiology broadly
assigned to one of five
groups
1. Drug/toxins
2. Infectious
Shorvon S and Ferlisi M. Brain 2011
Betjemann JP and Lowenstein DH. Lancet Neurol 2015
Turnbull D and Singatullina N. Minerva Anestesiol 2013
18. RSE basic info
Etiology broadly
assigned to one of five
groups
1. Drug/toxins
2. Infectious
3. Structural
Shorvon S and Ferlisi M. Brain 2011
Betjemann JP and Lowenstein DH. Lancet Neurol 2015
Turnbull D and Singatullina N. Minerva Anestesiol 2013
19. RSE basic info
Etiology broadly
assigned to one of five
groups
1. Drug/toxins
2. Infectious
3. Structural
4. Metabolic
Shorvon S and Ferlisi M. Brain 2011
Betjemann JP and Lowenstein DH. Lancet Neurol 2015
Turnbull D and Singatullina N. Minerva Anestesiol 2013
20. RSE basic info
Etiology broadly
assigned to one of five
groups
1. Drug/toxins
2. Infectious
3. Structural
4. Metabolic
5. Uncommon genetic
disorders
Shorvon S and Ferlisi M. Brain 2011
Betjemann JP and Lowenstein DH. Lancet Neurol 2015
Turnbull D and Singatullina N. Minerva Anestesiol 2013
21. Why does RSE occur?
Microcellular damage
↑ glutamate and NMDA receptor
expression
↓ GABA receptors
↑ BBB permeability ↑ K+ levels
hyperexcitation
Hyperexcitation Ca2+ influx
apoptosis
Micro to macro
Enough microcellular damage =
macro cerebral damage
Further lowers seizure threshold
and increased epileptogenicity
Kapur J and Macdonald RL. J Neurosci 1997
Shorvon S and Ferlisi M. Brain 2011, 2012
Rosati M, et al. Neurology 2013
24. AED selection in RSE
Levetiracetam Valproate
Phenobarbital
Phenytoin
Yasiry Z and Shorvon S. Seizure 2014
25. AED selection criteria
Synowiec A, et al. Epilepsy Research 2012 Miró J, et al. Seizure 2013
Aiguabella M, et al. Seizure 2011 Shorvon S and Ferlisi M. Brain 2012
26. AED selection
Turnbull D and Singatullina N. Minerva Anestesiol 2013
Zeiler FA, et al. Seizure 2015
27. IV Anesthesia for RSE
John Hughlings Jackson in 1888
“Chloral is the best drug; and if the fits are very frequent,
ehterisation will help”
Three main drugs studied
Barbiturates
Midazolam
Propofol
Ketamine*
Claassen J, et al. Epilepsia 2002
Shorvon S and Ferlisi M. Brain 2011
28. Comparison of IV anesthetics
Claassen J, et al. Epilepsia 2002
Shorvon S and Ferlisi M. Brain 2012
34. Claassen meta-analysis conclusions
Barbiturates show better efficacy**
Burst suppression has fewer breakthrough seizures
Mortality is NOT dependent on:
Drug selection
EEG characteristics
Authors suggested a RCT be done
38. IV anesthesia meta-analyses summary
No agent is “better” than the other
Treating to background suppression
Leads to fewer breakthrough seizures
Trends towards lower treatment failure
Trends towards lower withdrawal seizure rate
Does not lower mortality
Increases hypotension
39. Ketamine
NMDA antagonist
Neuroprotective?
Sympathomimetic
Less sedating compared to other IV anesthesia
Meta-analysis through 2012 had 20/24 responders
Small 2013 retrospective study had 6/9 responders
Mostly patients with epilepsy
“Large” multicenter retrospective study had 19/60 responders
Mostly patients with NORSE
Only 2/46 had MRS<2
Concern for cerebellar atrophy
This case study confounded by long term PHT usage
Rosati R, et al. Neurology 2013 Gaspard N, et al. Epilepsia 2013
Ubogu EE, et al. Epilepsy Behavior 2003
41. Surgery
Primarily considered in focal RSE
33/36 controlled RSE
27 with “good” outcomes
Lhatoo SD and Alexopoulos AV. Epilepsia 2007 Alexopoulos A, et al. Neurology 2005
Ma X, et al. Epilepsy Research 2001 Shorvon S and Ferlisi M. Brain 2012
44. Hypothermia
First 3 cases reported in 1984
Grew out of intraoperative experience of putting cold
water on seizing brain
Rat data demonstrates decreased cerebral damage
compared to normothermic and hyperthermic groups
Suggested exclusion criteria
Immunosuppression
Hemodynamically unstable
Coagulopathy
Active infection
Orlowski JP, et al. Critical Care Medicine 1984 Rossetti AO. Epilepsia 2011
Kowski AB, et al. Brain Research 2012 Corry JJ, et al. Neurocritical Care 2008
45. Hypothermia
3 pediatric patients in 1984
Thiopental to burst suppression
2/3 patients recovered
4 adult patients in 2008
Target temp of 31 – 33°C
24 hour hypothermic period
2/4 seizure free
Orlowski JP, et al. Critical Care Medicine 1984
Corry JJ, et al. Neurocritical Care 2008
46. Immunotherapy
Considered in NORSE
One series with plasmapheresis, one with IVIG
8 patients total
5/8 responder rate
2 died (underlying disease)
Beneficial independent effect?
Li J, et al. Seizure 2013
Gall C, et al. Seizure 2013
Shorvon S and Ferlisi M. Brain 2011
53. Works cited
Abend NS, et al. “Impact of Continuous EEG Monitoring on Clinical Management in Critically Ill Children”. Neurocrit Care 2011
Aug;15(1):70-5
Alexopoulos, A., et al. “Resective surgery to treat refractory status epilepticus in children with focal epileptogenesis.” Neurology, v. 64 issue 3,
2005, p. 567-70.
Claassen, J.; Hirsch, LJ.; Emerson, RG.; Mayer, SA. “Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a
systematic review.” Epilepsia (Series 4), v. 43 issue 2, 2002, p. 146-53.
Claassen, J, et al. “Detection of electrographic seizures with continuous EEG monitoring in critically ill patients”. Neurology 2004;62:1743-1748
Cooper, AD.; Britton, JW.; Rabinstein, AA. “Functional and cognitive outcome in prolonged refractory status epilepticus.” Archives of
Neurology, v. 66 issue 12, 2009, p. 1505-9.
Corry, JJ.; Dhar, R.; Murphy, T.; Diringer, MN. “Hypothermia for refractory status epilepticus.” Neurocritical Care, v. 9 issue 2, 2008, p. 189-97.
De Marchis GM, et al. “Seizure burden in subarachnoid hemorrhage associated with functional and cognitive decline”. Neurology 2016;86:253-
60
Drislane, FW., et al. “Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours.” Epilepsia (Series 4),
v. 50 issue 6, 2009, p. 1566-71.
Gall, CR.; Jumma, O.; Mohanraj, R. “Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early
immunotherapy.” Seizure : the journal of the British Epilepsy Association, v. 22 issue 3, 2013, p. 217-20.
Gaspard N, et al. “Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study”. Epilepsia,
54(8);1498-1503
Gilmore EJ, et al. “Acute brain failure in severe sepsis: a prospective study in the medical intensive care unit utilizing continuous EEG
monitoring”. Intensive Care Med 2015 APR;41(4):686-94
Grover EH, Nazzal Y, and Hirsch LJ. “Treatment of Convulsive Status Epilepticus”. Curr Treat Options Neurol. 2016 Mar;18(3):11
Hocker, SE., et al. “Predictors of outcome in refractory status epilepticus.” JAMA Neurology, v. 70 issue 1, 2013, p. 72-7.
Husain Am, Horn GJ, Jacobson MP. “Non-convulsive status epilepticus: usefulness of clinical feature sin selecting patients for urgent EEG”
JNNP 2003;74:189-91
Kapur, J.; Macdonald, RL. “Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell
GABAA receptors.” Journal of Neuroscience, 17 (19), 1997;7532-40
Kilbride RD, et al. “How Seizure Detection by Continuous Electroencephalographic Monitoring Affects the Prescribing of Antiepileptic
Drugs”. Arch Neurol 2009;66(6):723-8
Köhrmann, et al. “CSF-air-exchange for pharmacorefractory status epilepticus.” Journal of Neurology, v. 253 issue 8, 2006, p. 1100-1.
54. Works cited
Laccheo I, et al. “Non-convulsive Status Epilepticus and Non-convulsive Seizures in Neurological ICU Patients”. 2015 Apr;22(2):202-11
Lambrecq, V., et al. “Refractory status epilepticus: electroconvulsive therapy as a possible therapeutic strategy.” Seizure, v. 21 issue 9, 2012, p.
661-4.
Lhatoo, SD.; Alexopoulos, AV. “The surgical treatment of status epilepticus.” Epilepsia (Series 4), v. 48 Suppl 8, 2007, p. 61-5.
Li, J.; Saldivar, C.; Maganti, RK. “Plasma exchange in cryptogenic new onset refractory status epilepticus.” Seizure : the journal of the British
Epilepsy Association, v. 22 issue 1, 2013, p. 70-3.
Ma, X.; Liporace, J.; O'Connor, MJ.; Sperling, MR. “Neurosurgical treatment of medically intractable status epilepticus.” Epilepsy Research, v. 46
issue 1, 2001, p. 33-8.
Mayer, SA., et al. “Refractory status epilepticus: frequency, risk factors, and impact on outcome.” Archives of Neurology, v. 59 issue 2, 2002, p.
205-10.
Meierkord H and Holtkamp M. “Non-convulsive status epilepticus in adults: clinical forms and treatment”. Lancet Neurol 2007; 6:329-39
Mirsattari, SM.; Sharpe, MD.; Young, GB. “Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and
desflurane.” Archives of Neurology, v. 61 issue 8, 2004, p. 1254-9.
Quek, AM., et al. “Autoimmune epilepsy: clinical characteristics and response to immunotherapy.” Archives of Neurology, v. 69 issue 5, 2012, p.
582-93.
Rosati, A., et al. “Efficacy and safety of ketamine in refractory status epilepticus in children.” Neurology, v. 79 issue 24, 2012, p. 2355-8.
Rossetti, AO.; Logroscino, G.; Bromfield, EB. “Refractory status epilepticus: effect of treatment aggressiveness on prognosis.” Archives of
Neurology, v. 62 issue 11, 2005, p. 1698-702.
Rossetti, AO. “What is the value of hypothermia in acute neurologic diseases and status epilepticus?.” Epilepsia (Series 4), v. 52 Suppl 8, 2011,
p. 64-6.
Rossetti, AO., et al. “A randomized trial for the treatment of refractory status epilepticus.” Neurocritical Care, v. 14 issue 1, 2011, p. 4-10.
Shafi MM, et al. “Absence of early epileptiform abnormalities predicts lack of seizures on continuous EEG”. Neurology 2012;79:1796-1801
Shneker BF and Fountain NB. “Assessment of acute morbidity and mortality in nonconvulsive status epilepticus”. Neurology 2003;61:1066-73
Shorvon, S.; Ferlisi, M. “The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment
protocol.” Brain: A Journal of Neurology, v. 134 issue Pt 10, 2011, p. 2802-18.
Shorvon, S.; Ferlisi, M. “The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for
therapy.” Brain: A Journal of Neurology, v. 135 issue Pt 8, 2012, p. 2314-28.
55. Works cited
Smith, M. “Anesthestic agents and status epilepticus.” Epilepsia (Series 4), v. 52 Suppl 8, 2011, p. 42-4.
Sutter R, et al. “Continuous video-EEG monitoring increases detection rate of nonconvulsive status epilepticus in the ICU”. Epilepsia
2011;52(3):453-457
Sutter R, et al. “EEG for Diagnosis and Prognosis of Acute Nonhypoxic Encephalopathy: History and Current Evidence”. J Clin Neurophysiol
2015;32: 456–464
Turnbull, D.; Singatullina, N. “Manuscript title: Super Refractory Status Epilepticus: The development of a paradigm for critical care
management.” Minerva Anestesiologica, 2013 Feb 18 [Epub ahead of print]
Vespa P, et al. “Metabolic Crisis Occurs with Seizures and Periodic Discharges after Brain Trauma”. Ann Neurol 2016 [Epub ahead of print]
Williams RP, et al. “Impat of an ICU EEG monitoring pathway on timeliness of therapeutic intervention and electrographic seizure
termination”. Epilepsia 2016 [Epub ahead of print]
Yasiry Z and Shorvon SD. “The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status
epilepticus: A meta-analysis of published studies”. Seizure 23 (2014) 167-174
Zeiler FA, et al. “Lidocaine for status epilepticus in adults”. Seizure 31 (2015) 41-48
Editor's Notes
Left numbers are mortality
Right numbers are percentage of the previous stage in which that stage occurs
Two ways to answer this question
Left graph shows that the longer you monitor for, the more likely you are to diagnose a nonconvulsive seizure if present
Right graph shows that if the EEG is normal in the first 30 minutes, there is about a 3% chance of seizure.
So in essence, if you have a high suspicion of NCS, video EEG is the appropriate test. A low pretest probability would probably see a one hour EEG as sufficient.
Periodic findings lead to seizures in a high rate of patients
PLEDs perhaps warrant a longer monitoring time, as a first seizure can present greater than 24 hours after
Top study establishes some physiological basis for possible injury – surface and intracortical depth electrodes with cerebral microdialysis – Microdialysis showed increased lactate/pyruvate levels during seizures and periodic patterns – this only establishes acute injury and does not
Bottom study shows correlation between NCSE time and 3 month functional outcome – Study comparing length of NCSE in SAH patients and assessing function by telephone interview 3 months later – They found each hour correlated with a 10% higher odds of death/disability at 3 months
These two studies are notable that they address acute, significant neurological injury and not chronic epilepsy
The last point is that etiologies that are relatively “easy” to treat have the best outcomes
Some mortality rates may be due to the underlying disease rather than the status as well. In other words, the status is a symptom rather than a cause
There is precious little data on this subject. This meta-analysis from 2014 analyzed 22 studies and found levetiracetam, phenobarbital, and valproate were all similarly efficacious while phenytoin lagged behind.
Levetiracetam – 68.5%
Phenobarbital – 73.6%
Valproate – 75.7%
Phenytoin – 50.2%
The Established status epilepticus treatment trial is underway and will compare PHT, LVT, and VPA in benzodiazepine resistant status epilepticus
Lidocaine – 76 patients studied – 70% seizure cessation, the majority with phenytoin having already failed – suggests safety in setting of other sodium channel blockers – did have 23% relapse rate
Much of the work we know about comparison between these 3 drugs is from a 2002 meta-analysis of 28 studies from 1980-2001. As with all meta-analysis, this one had some difficulties with the heterogeneity of the study designs and definitions. However, a few very useful conclusions were able to be made
Two important things to note.
Pentobarb had a relatively low number of continuous monitoring.
Pentobarb also had a higher percentage of their patients tirated to EEG background suppression.
Only RCT done for RSE. It compared propofol to thiopental, with a goal of burst suppression for treatment.
Stopped prematurely at 24 patients (goal 150 patients) due to low recruitment
Only finding was that there was longer ventilation with barbiturates
There was a trend towards increased efficacy with propofol.
Median dose of propofol required for burst suppression was 5 mg/kg/h
Median dose of thiopental required was 6.7mg/kg/h
54 MDZ 585 MDZ (306 cases from one study), so subtracting that, 54 MDZ 279 MDZ
33 106 PRO
106 192 BARB
This means in the intervening time, there have been an additional 690 patients put into the pool. Again, only 24 of these cases were from a RCT. The quality of data is only as good as what we put in, so we are limited as to stringent data that can be taken away.
Important to note that the breakthrough seizures do not include patients who had a seizure relapse, which was controlled by increasing initial medicine. Those numbers are 7% of MDZ, 12% of PRO, and 6% of BARB.
With regards to withdrawal seizures, it was interesting to note that 93% of those that were reintroduced to MDZ regained control, as compared to only 47% of PRO and 22% of BARB.
More clearly illustrates the point of the difficulty in interpreting meta-analyses. Different methadologies were used for these studies, which yielded very different information. Always should use caution when interpreting these results.
Suggested mechanisms of decreased damage include:
Decreased brain metabolism
Inhibition of glutamate release
Reduction of free radical production
Mitigation of reperfusion injury
Decreased damage to BBB with resultant decreased cerebral edema
Decrease of proinflammatory reactions.
1 patient who did poorly in 1984 series had Rasmussen’s encephalitis
2 patients who died had limbic encephalitis and hepatic encephalopathy. Limbic encephalitis case died due to pertonitis after G-tube insertion
Retrospective review of 119 patients from BI Deaconess. Only 35% of these patients survived. These patients represented all SE, (both anoxic and non-anoxic status).